Comparison of GLP-1RAs vs Other Pharmacotherapy for Obesity
Background: The Centers for Disease Control and Prevention (CDC) reports that 42% of adults in the United States (US) are obese, and 10% are severely obese. Obesity has many known associated health risks, and successful treatment decreases those risks. Management always includes diet and lifestyle...
Saved in:
| Main Authors: | Andrew Overholser, Eric Czech, Linda Speer, Joel Wilson, Alex Overholser |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The University of Toledo
2025-02-01
|
| Series: | Translation |
| Subjects: | |
| Online Access: | https://openjournals.utoledo.edu/index.php/translation/article/view/1218 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Role of physical activity in GLP-1 receptor agonist therapy for obesity treatment
by: Łukasz Zdziebkowski, et al.
Published: (2025-07-01) -
Insights into the Efficacy of GLP-1 Agonists and Dual Agonists: Semaglutide and Tirzepatide in Obesity and Type 2 Diabetes
by: Laura Opalska, et al.
Published: (2024-12-01) -
Semaglutide, liraglutide and tirzepatide: Comparison of effectiveness in the treatment of obesity – a literature review
by: Karolina Baran, et al.
Published: (2024-12-01) -
Physician Perceptions of the Safety and Efficacy of GLP-1 Receptor Agonists: Underestimation of Cardiovascular Risk Reduction and Discrepancies with Clinical Evidence
by: Srikanth Krishnan, et al.
Published: (2025-01-01) -
Novel findings regarding treatment obesity and weight-related comorbidities – the systemic literature review
by: Karina Urbańska, et al.
Published: (2025-01-01)